Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alvaro AlonsoAlanna A MorrisAshley I NaimiAniqa B AlamLinzi LiVinita SubramanyaLin Yee ChenPamela L LutseyPublished in: Journal of the American Heart Association (2024)
Use of ARNi and SGLT2i in patients with AF and HF is suboptimal, particularly among women and older individuals, though use is increasing. These results underscore the need for understanding reasons for these disparities and developing interventions to improve adoption of evidence-based therapies among patients with comorbid AF and HF.
Keyphrases
- heart failure
- atrial fibrillation
- acute heart failure
- electronic health record
- physical activity
- polycystic ovary syndrome
- angiotensin ii
- left ventricular
- big data
- healthcare
- angiotensin converting enzyme
- middle aged
- type diabetes
- skeletal muscle
- binding protein
- machine learning
- metabolic syndrome
- affordable care act
- insulin resistance
- deep learning